Article
EGFR-TKI-induced Factor V deficiency in a patient with advanced non-small cell lung cancer: The first case report.
Lung cancer (Amsterdam, Netherlands) - 1 Aug 2024
Yoshizaki Chinatsu, Yoshida Yuki, Nohmi Shiho, Go Yoshihiro, Kusakado Rui, Kawamura Saori, Inoue Daisuke, Kabasawa Nobuyuki, Yamaguchi Fumihiro
Abstract excerpt
Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is routinely prescribed as first-line therapy for advanced non-small cell lung cancer, regardless of the presence of the T790M resistance mutation. This study reports a rare case of Factor V inhibitor detection during osimertinib therapy in a patient with lung adenocarcinoma. These findings underscore the...
Topics
- Humans
- Acrylamides
- Adenocarcinoma of Lung
- Aniline Compounds
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Factor V Deficiency
- Indoles
- Lung Neoplasms